EA201892244A1 - МОНОВАЛЕНТНЫЙ ИНГИБИТОР ВЗАИМОДЕЙСТВИЯ huTNFR1 - Google Patents

МОНОВАЛЕНТНЫЙ ИНГИБИТОР ВЗАИМОДЕЙСТВИЯ huTNFR1

Info

Publication number
EA201892244A1
EA201892244A1 EA201892244A EA201892244A EA201892244A1 EA 201892244 A1 EA201892244 A1 EA 201892244A1 EA 201892244 A EA201892244 A EA 201892244A EA 201892244 A EA201892244 A EA 201892244A EA 201892244 A1 EA201892244 A1 EA 201892244A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hutnfr1
inhibitor
interaction inhibitor
monovalent interaction
monovalent
Prior art date
Application number
EA201892244A
Other languages
English (en)
Inventor
Роланд Контерман
Клаус Пфиценмайер
Фабиан Рихтер
Кирстин Цетлиц
Петер Шойрих
Андреас Герман
Original Assignee
Универзитэт Штутгарт
Балиофарм Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Универзитэт Штутгарт, Балиофарм Аг filed Critical Универзитэт Штутгарт
Publication of EA201892244A1 publication Critical patent/EA201892244A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Изобретение обеспечивает ингибитор рецептора huTNFR1, который представляет собой человеческую или гуманизированную конструкцию антитела, которая моновалентно узнает huTNFR1 через антигенсвязывающий фрагмент, которая характеризуется специфическими CDR-последовательностями, его фармацевтический препарат, способ получения ингибитора и медицинское применение ингибитора.
EA201892244A 2016-04-05 2017-04-04 МОНОВАЛЕНТНЫЙ ИНГИБИТОР ВЗАИМОДЕЙСТВИЯ huTNFR1 EA201892244A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16163822 2016-04-05
PCT/EP2017/057997 WO2017174586A1 (en) 2016-04-05 2017-04-04 MONOVALENT INHIBITOR OF huTNFR1 INTERACTION

Publications (1)

Publication Number Publication Date
EA201892244A1 true EA201892244A1 (ru) 2019-04-30

Family

ID=55661321

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892244A EA201892244A1 (ru) 2016-04-05 2017-04-04 МОНОВАЛЕНТНЫЙ ИНГИБИТОР ВЗАИМОДЕЙСТВИЯ huTNFR1

Country Status (15)

Country Link
US (1) US10689452B2 (ru)
EP (1) EP3440110B1 (ru)
JP (1) JP6784775B2 (ru)
KR (1) KR102229083B1 (ru)
CN (1) CN109641958B (ru)
AU (1) AU2017245612B2 (ru)
BR (1) BR112018070452A2 (ru)
CA (1) CA3019692A1 (ru)
EA (1) EA201892244A1 (ru)
ES (1) ES2911442T3 (ru)
IL (1) IL262111B2 (ru)
MA (1) MA43764A (ru)
MX (1) MX2018012061A (ru)
SG (1) SG11201808680RA (ru)
WO (1) WO2017174586A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019102023A1 (en) 2017-11-27 2019-05-31 Baliopharm Ag ANTI-huTNFR1 THERAPY OF NONALCOHOLIC STEATOHEPATITIS
EP3810095A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
EP1972637B1 (en) * 2007-03-19 2011-06-29 Universität Stuttgart huTNFR1 selective antagonists
AR078763A1 (es) * 2009-10-27 2011-11-30 Glaxo Group Ltd Polipeptidos anti factor de necrosis tumoral 1 (anti-tnfr1) estables, dominios variables de anticuerpos y antagonistas
PL2616489T3 (pl) * 2010-09-16 2017-07-31 Baliopharm Ag Przeciwciało anty-huTNFR1

Also Published As

Publication number Publication date
EP3440110B1 (en) 2022-01-26
MA43764A (fr) 2021-06-02
CA3019692A1 (en) 2017-10-12
ES2911442T3 (es) 2022-05-19
KR20190003947A (ko) 2019-01-10
IL262111A (en) 2018-11-29
US10689452B2 (en) 2020-06-23
IL262111B2 (en) 2023-08-01
AU2017245612B2 (en) 2020-08-27
CN109641958A (zh) 2019-04-16
IL262111B1 (en) 2023-04-01
WO2017174586A1 (en) 2017-10-12
CN109641958B (zh) 2023-10-31
EP3440110A1 (en) 2019-02-13
SG11201808680RA (en) 2018-11-29
MX2018012061A (es) 2019-12-16
JP2019516354A (ja) 2019-06-20
US20190144555A1 (en) 2019-05-16
BR112018070452A2 (pt) 2019-02-05
AU2017245612A1 (en) 2018-10-11
KR102229083B1 (ko) 2021-03-18
JP6784775B2 (ja) 2020-11-11

Similar Documents

Publication Publication Date Title
CY1122245T1 (el) Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου
CY1124033T1 (el) Δοσολογια και χορηγηση μη φουκοζυλιωμενων αντισωματων anti-cd40
EA201791050A1 (ru) Конъюгаты антител и лекарственных средств
PH12017502161A1 (en) Anti-cd40 antibodies and uses thereof
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
MX2022002364A (es) Anticuerpos anti-pd-l1.
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
CL2016001979A1 (es) Métodos de tratamiento de enfermedad de alzheimer.
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
NZ727024A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
EA201691541A1 (ru) Новые анти-baff антитела
EA201691438A1 (ru) Антитело, которое связывается с erbb-2 и erbb-3
EA201792590A1 (ru) КОНЪЮГАТ АНТИТЕЛА ПРОТИВ ErbB2 И ЛЕКАРСТВЕННОГО СРЕДСТВА И ЕГО КОМПОЗИЦИЯ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ
MX2018012493A (es) Métodos para controlar y tratar el cáncer.
BR112017009817A2 (pt) anticorpos anti-il-1beta e métodos de utilização
TN2017000072A1 (en) Combination alzheimer therapy using anti-n3pglu abeta antibodies + a bace inhibitor
BR112016027881A2 (pt) antagonistas de pdl-1 e pd-1 para o tratamento de cânceres negativos para o hpv
NZ728981A (en) Anti-ceramide antibodies
BR112017015880A2 (pt) anticorpos, usos e métodos
EA201890340A1 (ru) Моноклональное антитело-ингибитор фактора xiia
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
EA201892313A1 (ru) Гуманизированные антитела против clever-1 и их применение
MX2018004406A (es) Anticuerpo monoclonal bactericida contra la klebsiella pneumoniae.
EA201692482A1 (ru) Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
EA201892244A1 (ru) МОНОВАЛЕНТНЫЙ ИНГИБИТОР ВЗАИМОДЕЙСТВИЯ huTNFR1